Zhang Tonghao, Huang Shuoyin, Guo Yanli, Jin Jing, Yan Wu, Wang Panpan, Fang Yuying, Liu Yingying, Pan Yuting, Fan Zhidan, Yu Haiguo
Department of Rheumatology and Immunology, Children's Hospital of Nanjing Medical University, Nanjing, China.
Department of Child Health Care, Children's Hospital of Nanjing Medical University, Nanjing, China.
Front Pediatr. 2023 May 26;11:1122233. doi: 10.3389/fped.2023.1122233. eCollection 2023.
In children with enthesitis-related arthritis (ERA), the hip and sacroiliac joint function might be impaired if not properly treated. We sought to evaluate the effectiveness of anti-tumor necrosis factor-α (TNF-α) therapy using the inflammatory indicators, Juvenile Arthritis Disease Activity Score 27 (JADAS27) and magnetic resonance imaging (MRI).
We conducted a single-center retrospective study of 134 patients with ERA. We evaluated the effect of anti-TNF therapy on the inflammatory indicators, active joint count, MRI quantitative score, and JADAS27 over 18 months. We used the Spondyloarthritis Research Consortium of Canada (SPARCC) and the Hip Inflammation MRI Scoring System (HIMRISS) scoring systems for hip and sacroiliac joints scoring.
The average age of onset of children with ERA was 11.62 ± 1.95 years, and they were treated with disease-modifying antirheumatic drugs (DMARDs) combined with biologics ( = 87, 64.93%). There were no differences in HLA-B27 positivity between the biologics and non-biologics treatment groups [66 (49.25%) vs 68 (50.75%), > 0.05]. Children who received anti-TNF (71 received etanercept, 13 adalimumab, 2 golimumab, and 1 infliximab) therapy improved significantly. Children with ERA used DMARDs and biologics at baseline (Group A) were followed up to 18 months, and their active joint count (4.29 ± 1.99 vs. 0.76 ± 1.33, = 0.000), JADAS27 (13.70 ± 4.80 vs. 4.53 ± 4.52, = 0.000) and MRI quantitative scores ( = 0.001) were significantly lower than those at baseline. Some of the patients ( = 13, 9.70%) were treated with DMARDs at the onset of the disease, but did not show significant improvement (Group B). After 6-18 months of switching to anti-TNF therapy, related indicators of the children were significantly lower than at baseline and 1 month ( < 0.013). At 18 months, a total of 33 patients ( = 74, 44.59%) in Group A and 7 ( = 13, 53.85%) in Group B reached inactive state.
Eighteen months after diagnosis, anti-TNF therapy was found to be effective in children diagnosed with ERA. MRI is important for the early diagnosis of juvenile idiopathic arthritis. TNF-α inhibitors can significantly improve the clinical manifestations of sacroiliac joint and hip involvement in patients with ERA. Overall, the real-world study provides more evidence for precision diagnosis and treatment for other hospitals, families and patients.
在附着点炎相关关节炎(ERA)患儿中,如果治疗不当,髋关节和骶髂关节功能可能会受到损害。我们试图使用炎症指标、青少年关节炎疾病活动评分27(JADAS27)和磁共振成像(MRI)来评估抗肿瘤坏死因子-α(TNF-α)治疗的有效性。
我们对134例ERA患者进行了单中心回顾性研究。我们评估了抗TNF治疗在18个月内对炎症指标、活跃关节计数、MRI定量评分和JADAS27的影响。我们使用加拿大脊柱关节炎研究联盟(SPARCC)和髋关节炎症MRI评分系统(HIMRISS)评分系统对髋关节和骶髂关节进行评分。
ERA患儿的平均发病年龄为11.62±1.95岁,他们接受了改善病情抗风湿药(DMARDs)联合生物制剂治疗(n = 87,64.93%)。生物制剂治疗组和非生物制剂治疗组之间HLA-B27阳性率无差异[66例(49.25%)对68例(50.75%),P>0.05]。接受抗TNF治疗的患儿(71例接受依那西普,13例接受阿达木单抗,2例接受戈利木单抗,1例接受英夫利昔单抗)有显著改善。基线时使用DMARDs和生物制剂的ERA患儿(A组)随访至18个月,其活跃关节计数(4.29±1.99对0.76±1.33,P = 0.000)、JADAS27(13.70±4.80对4.53±4.52,P = 0.000)和MRI定量评分(P = 0.001)均显著低于基线水平。部分患者(n = 13,9.70%)在疾病发作时接受了DMARDs治疗,但未显示出显著改善(B组)。转为抗TNF治疗6 - 18个月后,患儿的相关指标显著低于基线水平和1个月时(P<0.013)。在18个月时,A组共有33例患者(n = 74,44.59%)和B组7例患者(n = 13,53.85%)达到非活动状态。
诊断18个月后,发现抗TNF治疗对诊断为ERA的患儿有效。MRI对幼年特发性关节炎的早期诊断很重要。TNF-α抑制剂可显著改善ERA患者骶髂关节和髋关节受累的临床表现。总体而言,这项真实世界研究为其他医院、家庭和患者的精准诊断和治疗提供了更多证据。